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ORIGINAL ARTICLE
Can unilateral, progressive or sudden hearing loss be immune-mediated in
origin?
Francesca Atturo, Roberta Colangeli, Giorgio Bandiera, Maurizio Barbara and Simonetta Monini
ENT Unit, NESMOS Department, Medicine and Psychology, Sapienza University, Rome, Italy
ABSTRACT
Objective: The aim of the present study was to demonstrate that the positivity of nonspecific
immunological tests could be found not only in bilateral hearing loss but also in unilateral cases, either
sudden or progressive.
Method: An observational case series study included subjects suffering from unilateral or bilateral, sud-
den or progressive, symmetric or asymmetric sensorineural hearing loss (SNHL). All the patients under-
went pure tone audiometry and the following battery of blood exams: anti-nuclear antibody (ANA),
extractable nuclear antigen (ENA) antibody screening, anti-thyroperoxidase (anti-TPO), anti-thyroglobu-
lin and anti-smooth muscle antibody (ASMA).
Results: The positivity to nonspecific immunological test was found in nearly 70% of the study groups.
ASMA and ANA were found to be present in both bilateral and unilateral cases, without statistical
difference. Considering the correlation between positivity/negativity and systemic autoimmune pathol-
ogies, in the bilateral forms of hearing loss, a high incidence of thyroid pathologies has been identified,
with a higher percentage of systemic autoimmune diseases in respect to the normal population.
Conclusions: The nonspecific autoimmune tests are worth to be performed also when SNHL is not
bilateral and progressive, since an immunological mechanism could also underlie unilateral and sudden
SNHL cases.
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Introduction
Since more than three decades, a bilateral, progressive
form of sensorineural hearing loss (SNHL) has been
regarded as a possible immune disorder that affects the
inner ear. The clinical suspicion can be raised in presence
of involvement of three contiguous frequencies [1], rapid
progression over days to months [2] and a positive
response to corticosteroids treatment [3]. Hence, the term
of autoimmune or, better, immune-mediated inner ear dis-
ease (IMIED) has been coined. This nosological entity is
thought to be caused by antibodies or immune cells that
attack the inner ear and it may present as a localized pri-
mary disease or in association with a systemic autoimmune
disorder [3,4].
Elevated levels of sera immune complexes and anti-inner
ear antibodies have been described on patients affected by
progressive and/or sudden SNHL [5]. The reaction of sera
of patients with suspected IMIED showed a positive reac-
tion of their sera – at 68 KDa antibody – with HSP-70 pro-
teins extracted from bovine inner ear as well as with the
human ‘choline transporter-like protein 2’ or CTL2 [6,7].
In this regard, some authors have proposed a higher sensi-
tivity of nonspecific immunological tests for the detection
of IMIED [8]. Nevertheless, there is no consensus about
the type of diagnostic laboratory test that could correctly
identify an IMIED, due to their low grade of sensitivity
and specificity [6,9]. As far as nonspecific antigen-screen-
ing tests are concerned, some studies would suggest
restricting the laboratory tests only to anti-nuclear antibod-
ies (ANA), to immune-phenotype of peripheral blood
lymphocytes (PBL) [8] and to anti-endothelial antibodies
(AECA) [10].
From an audiological point of view, it is common belief
that immune-mediated hearing loss generally involves both
ears (80%), with symmetric or asymmetric hearing threshold
levels [4,11,12], although at its initial presentation, IMIED
may present in a fashion similar to that seen in sudden
SNHL, and involves only one ear [10,11].
The aim of the present study was to investigate on the
diagnostic role played by some nonspecific immunological
tests for substantiating the diagnosis of IMIED, and to test
them on a cohort of patients that also includes the unilateral
and sudden forms of SNHL, other than the classical bilateral
and progressive forms.
Material and methods
A consecutive series of subjects affected by unilateral or
bilateral, sudden or progressive, symmetric or asymmetric
SNHL were included in this study. Patients with diagnosis
of definite Meniere’s disease, retrocochlear pathologies or
over 65 years were excluded.
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All the patients underwent pure tone audiometry and the
following battery of blood exams to evaluate the immuno-
logical response:
 anti-nuclear antibody (ANA),
 extractable nuclear antigen (ENA) antibody screening,
 anti-thyroperoxidase (anti-TPO),
 anti-thyroglobulin
 anti-smooth muscle antibody (ASMA).
ANA determination was performed by indirect immuno-
fluorescence (IIF) and the definition of positivity expressed
as titre of 1:80, considering the values >80< 120 as slightly
positive, >120/160 mildly positive and >160 highly positive.
ENA screening was performed with the immuno-enzymatic
assay ELISA: the reference titre was <20 and the positivity
was considered slight for 20, mild for >20, high for 40.
The determination of ASMA autoantibody was performed
by IIF, having as reference titre the dilution of 1:40, consid-
ering slight positivity 1:40, mild 1:80 and high 1:100. Sera
positivity for anti-thyroglobulin and anti-thyroperoxidase
(anti-TPO) autoantibody, identified by immunochemilumi-
nescence, were titred >40 UI and >35 UI, respectively.
According to the hearing threshold at the time of obser-
vation, the patients were divided into two groups:
 Group A, which included 39 patients affected by bilateral
hearing loss (BHL);
 Group B, with 33 patients affected by unilateral hearing
loss (UHL).
The BHL group was further divided into symmetric
(BHLsy, n¼ 29 patients, 74.35% of the total) and asymmetric
(BHLasy, n¼ 10 patients, 25.65% of the total). The UHL
group was further divided into sudden (UHLs, n.22, 66.67% of
the total) and progressive (UHLp, n.11) (33.33% of the total).
The incidence of the positivity to nonspecific antibodies
was evaluated in the whole study sample and in the individ-
ual subgroups, and their correlation has been statistically
evaluated. The correlation between the positivity for the
individual antibody and the coexistence with systemic auto-
immune diseases has also been investigated. A positivity
scale was arbitrarily assigned to the assessed autoantibodies,
with a score between 1 and 3, where 1 represents slight posi-
tivity, 2 mild positivity and 3 high positivity. A statistical
two pair sample test (t-test) was applied for the evaluation
of the difference of positivity scores between Groups A and
B. The results were compared with a control group (C),
composed of 35 outpatients admitted for pathologies that
were not involving hearing.
The incidence of coexistence of a systemic autoimmune
disease was evaluated in both groups and the correlation
between systemic autoimmune disease and nonspecific auto-
antibody positivity and negativity was also analysed.
The study was conducted in accordance with the
Ethical Standards of the Local Committee on Human
Experimentation and with the Helsinki Declaration of 1975,
as revised in 1983.
Results
Seventy-two patients (24 males and 48 females, with a mean
age of 46.8 years, min. 14, max. 72) came to our observation
with an IMIED suspicion.
The nonspecific immunological tests resulted positive
in 48 patients (66.67%) of the entire study group. In the
BHL group, positivity was found in 26 patients (66.7%):
80.8% of them were affected by symmetric SNHL and
19.2% by asymmetric SHNL. A negative test was found in
33.3% of the BHL patients, 61.5% affected by symmetric
SNHL and 38.5% by asymmetric SNHL (Figure 1). In the
BHLsy group, 72.4% of patients resulted positive and
27.6% were negative. In BHLasy group, 50% resulted posi-
tive and 50% negative (Figure 2). In the UHL group, posi-
tivity was found in 66.7% of the patients (Figure 1).
Among the 22 patients affected by sudden SNHL, 59.1%
resulted positive and 40.9% negative; among the 11 patients
with progressive SNHL, 81.8% resulted positive and 18.2%
negative (Figure 3).
Considering altogether the bilateral and unilateral pro-
gressive SNHL (39þ 11 patients), a 70% of positivity to
nonspecific immunological tests was found.
As far as the positivity for the individual immunological
test is concerned, ANA resulted positive in 30.7% of BHL
and 33.3% of UHL; ENA resulted positive in 12.8% of
BHL and 3% of UHL, ASMA resulted positive in 23.1%
of BHL and 27.3% of UHL; anti-thyroglobulin antibodies
resulted positive in 10.2% of BHL and 24.2% of UHL; and
anti-thyroid peroxidase (anti-TPO) antibodies resulted posi-
tive in 18% of BHL and 24.2% of UHL (Figure 4). No statis-
tical difference in scores of positivity scale between bilateral
and unilateral forms was found. In the control group (C),
ANA was found positive in 17.14% [6] of the patients, with
a low titre (1:40), while ASMA resulted negative in the
whole control group.
Regarding the ANA and ASMA titres, no statistically
significant difference was found between BHL and UHL
groups, for both parametric and non-parametric tests
(Table 1).
Among the BHL patients who resulted positive to non-
specific autoantibody (n¼ 26), 3 (11.5%) had a systemic
autoimmune disease associated to thyroid disease, 7
(26.9%) had only a systemic autoimmune disease and 3
(11.5%) had an isolated thyroid disease. In the patients of
the same group, in whom the nonspecific auto-antibodies
tests were negative (n¼ 13), none had systemic auto-
immune disease associated to thyroid disease, 2 (15.4%)
had only a systemic autoimmune disease and none had
only a thyroid disease.
Among UHL patients who showed positivity for nonspe-
cific autoantibody (n¼ 22), 1 (4.5%) had systemic auto-
immune disease associated to thyroid disease, 2 (9%) had
only systemic autoimmune disease and 7 (31.8%) had only
thyroid disease. In those patients of the same group who
were negative to nonspecific autoantibody (n¼ 11), 1 (9%)
had only systemic autoimmune disease and none showed a
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systemic autoimmune disease associated to thyroid disease
or thyroid disease only (Figure 5).
Discussion
The typical profile of a suspected IMIED is actually based
on specific features that include the clinical course, the
immunological changes and the positive response to the
steroid therapy [12]. The pivotal element is represented by
the presence of hearing loss that usually drives the clinician
to further investigations, also on the ground of specific
characteristics, that is, if being uni- or bilateral and sudden
or progressive. When initially described, in fact, the IMIED
was recognised as always being both bilateral and progres-
sive, if not rapidly progressive [13]. When considering the
immunological component of this inner ear disorder, one
may recall that some evidence has been collected for the
inner ear to be affected in a variety of non-organ-specific
autoimmune diseases as a result of the interaction of genetic
factors, environmental pathogens and immune system
responses [14]. An autoimmune activity in idiopathic hear-
ing loss has been documented in viral labyrinthine infections
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Figure 2. Percentage of positivity to nonspecific immunological tests in symmetric and asymmetric bilateral hearing loss. BHLsy: symmetric bilateral hearing loss;
BHLasy: asymmetric bilateral hearing loss.
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Figure 1. Percentage of nonspecific immunological tests positivity and negativity in the study groups. BHL: bilateral hearing loss; UHL: unilateral hearing loss.
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considered as the major causes of auditory and vestibular
system pathologies, where the viral and bacterial infections
may contribute to the development and exacerbation of
autoimmune diseases [4,15,16]. The inner ear appears to be
the target for an immune-mediated disease that can be organ
or non-organ specific and the disease seems to have some
analogy with rapidly progressive glomerulonephritis: if not
treated, also often more quickly than 3 months, the pathology
may progress to a severe and irreversible damage [15]. More
specifically, ultrastructural signs of degeneration of the inner
ear structures, with atrophic changes of the acoustic nerve
and development of endolymphatic hydrops have also been
described [17]. As aforementioned, the clinical profile might
rise the suspicion of an IMIED, when major and/or minor
criteria are taken into consideration: BHL, systemic auto-
immune diseases, ANA >1:80, decrease of native T cells and
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Figure 4. Percentage of positivity for each nonspecific immunological test in bilateral hearing loss (BHL) and unilateral hearing loss (UHL). ANA: anti-nuclear anti-
body; ENA: extractable nuclear antigen antibodies; ASMA: anti-smooth muscle antibody; Anti-TPO: anti-thyroperoxidase; Antithyrogl: anti-thyroglobulin.
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Figure 3. Percentage of nonspecific immunological tests in sudden and progressive unilateral hearing loss. UHL: unilateral hearing loss.
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hearing recovery rate for corticosteroid >80% represent the
major ones; while unilateral hearing loss, young or middle
age of the patient, the female gender and hearing recovery
rate <80% for steroids play a minor role [18].
The purpose of the present study has been the assessment
of an IMIED as it can be solely based on the audiological
and nonspecific laboratory data, while the other important
feature for the diagnosis, that is, responsiveness to steroids
as ex juvantibus factor, was not at all taken into consider-
ation. Among the possible audiological pictures, also the
presence of an atypical presentation, such as it could be con-
sidered a unilateral or a sudden form of hearing loss, has
therefore purposely included, so as to compare two groups
of subjects with SNHL and their eventual positivity to non-
specific blood tests, chosen among those more frequently
positive in systemic autoimmune diseases (ANA, ENA,
ASMA anti-TPO and anti-thyroglobulin).
In this regard, despite its introduction and wide use during
the ‘90s, the Western Blot determination of HSP-70
(OTOblot) has lost much of its diagnostic importance for
IMIED, showing to be less sensitive than the ANA test, due
to the high percentage of positive values in the normal popu-
lation [8]. In this regard, a personal investigation carried out
on 56 patients, presenting with both unilateral and bilateral
SNHL (unpublished data) showed that none of the patients
with unilateral SNHL was OTOblot positive, against the 58%
positivity of nonspecific immunological tests; and only 9% of
bilateral SNHL were OTOblot positive against the 59% posi-
tivity of the nonspecific immunological tests. In addition, all
the OTOblot positive patients displayed positivity to the non-
specific immunological tests. These findings altogether have
motivated the discontinuation, in our clinical practice, of rou-
tine OTOblot and, instead, the use of nonspecific laboratory
tests that were the object of the present study.
When considering the ANA test, it should be kept in mind
that its positivity in the normal population increases with age
so that, in order to be significant, its titre values need to be
particularly high, that is, >1:160, as it was taken as a reference
also in the present study [7,10,14]. Our findings have, in fact,
confirmed the relevant positivity of ANA test, both in pro-
gressive and bilateral forms, but without significant differen-
ces between the two study groups.
According to the literature data and to our findings, the
ENA screening test would play as second line diagnostic
investigation, whilst the other antibodies (ASMA, anti-thyro-
globulin and anti-TPO), whose positivity was assessed in
some inner ear pathologies, such as Meniere’s disease, did
not show in our experience a similar sensitivity for IMIED.
Apart from the class of the selected antibodies, our study
would also suggest the importance of considering the appro-
priate titre values, considering that they could be higher in
the elderly general population.
0
5
10
15
20
25
30
35
posive BHL posive UHL negave BHL negave UHL
%
Correlaon between systemic autoimmune
diseases and aspecific auto-anbody posivity
systemic+thyroid
systemic
thyroid
Figure 5. Correlation between systemic autoimmune diseases and nonspecific autoantibody positivity and negativity in bilateral hearing loss (BHL) and unilateral
(UHL) hearing loss.
Table 1. ANA and ASMA positivity scores in bilateral hearing loss (BHL) and
unilateral hearing loss (UHL): no statistically significant differences were found
between the two groups (>0.05).
ANA ASMA
Bilateral HL Unilateral HL Bilateral HL Unilateral HL
2 1 1 1
1 1 1 1
3 1 1 3
1 1 1 2
1 1 2 1
2 1 2 1
3 1 1 1
1 1 1 1
1 2 1 2
1 2
1 3
3 1
ANA: anti-nuclear antibodies; ASMA: anti-smooth muscle antibodies.
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Our results have also shown that the positivity for non-
specific tests plus the organ-specific anti-thyroid test was
high (66.7%) in both groups (unilateral and bilateral), with-
out statistically significant differences. A high positivity was
found for ANA and ASMA, but both in bilateral and unilat-
eral cases and without differences in the scale of positivity,
whilst a statistical significant difference was found in com-
parison to the normal population.
Moreover, when evaluating the coexistence of a systemic
autoimmune disease or a thyroid disease and their associa-
tions, both bilateral and unilateral SNHL showed a significant
correlation only with an active thyroid disease. As far as the
correlation between the thyroidal pathology and the positivity
for anti-thyroglobulin and anti-TPO in the two main study
groups is concerned, a high correlation was found in both
groups, with higher values in the unilateral group. It is there-
fore our opinion that it would be useful to add to ANA and
ASMA tests also the titration of anti-thyroglobulin and anti-
TPO antibodies, especially in patients suffering by unilateral
SNHL without evidence of thyroid pathology.
In bilateral SNHL subjects, a higher percentage of positiv-
ity was found in the symmetric forms that, therefore, would
seem to be highly correlated to the nonspecific positivity to
autoantibody test.
Another interesting finding from our study is that the
positivity of the nonspecific battery test was higher in the
sudden SNHL group. One may thus suggest that the unilat-
eral SNHL, when sudden in onset, is more likely to have a
contralateral involvement over time than the unilateral, pro-
gressive form.
On the base of this experience, it is likely to assume that
the nonspecific antigen screening tests retain a higher diag-
nostic value in respect to the specific ones. The diagnostic
value of nonspecific autoantibody is not dependant from a
cause–effect relation, but is rather related to an epidemio-
logical and statistical association, so that the positivity to a
particular autoantibody might provide important informa-
tion regarding the disease profile, the responsiveness of
patients to the therapy and could also eventually differenti-
ate the prognosis.
A systemic disease should produce bilateral rather than
unilateral ear symptoms. As a consequence of an immuno-
logical mechanism in the pathogenesis of SNHL, it could
also be supposed that both sides could be compromised.
The present study has shown that the detection of sero-
logical nonspecific inner ear auto-antibodies, such as ANA
and ASMA, that are highly positive in the suspected IMIED
in respect to the general population, may be useful to sug-
gest a non-organ-specific immune mediated disorder, not
only in bilateral SNHL but also in the unilateral forms. The
detection of anti-thyroglobulin and anti-TPO may be useful
in suspected IMIED not only in patients with systemic auto-
immune diseases but mostly in those who are asymptomatic
for this kind of pathologies. Further studies on a larger
population sample would be necessary to support this
hypothesis and to clarify the eventual simultaneous
modification of hearing loss and autoantibody levels with
time and therapy.
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